Marie-Karelle Riviere
Marie-Karelle Riviere
Sanofi-Aventis R&D
Verified email at sanofi.com
Title
Cited by
Cited by
Year
A Bayesian dose‐finding design for drug combination clinical trials based on the logistic model
MK Riviere, Y Yuan, F Dubois, S Zohar
Pharmaceutical statistics 13 (4), 247-257, 2014
492014
Designs of drug-combination phase I trials in oncology: a systematic review of the literature
MK Riviere, C Le Tourneau, X Paoletti, F Dubois, S Zohar
Annals of Oncology 26 (4), 669-674, 2015
432015
Competing designs for drug combination in phase I dose‐finding clinical trials
MK Riviere, F Dubois, S Zohar
Statistics in medicine 34 (1), 1-12, 2015
412015
A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent
MK Riviere, Y Yuan, F Dubois, S Zohar
Journal of the Royal Statistical Society: Series C (Applied Statistics) 64 …, 2015
332015
Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization
MK Riviere, Y Yuan, JH Jourdan, F Dubois, S Zohar
Statistical methods in medical research 27 (2), 466-479, 2018
292018
An MCMC method for the evaluation of the Fisher information matrix for non-linear mixed effect models
MK Riviere, S Ueckert, F Mentré
Biostatistics 17 (4), 737-750, 2016
172016
Cephalometric assessment of craniofacial dysmorphologies in relation with Msx2 mutations in mouse
Y Simon, A Marchadier, MK Riviere, K Vandamme, F Koenig, F Lezot, ...
Orthod Craniofac Res. 17 (2), 92-105, 2014
102014
Improved Confidence Intervals and P-Values by Sampling from the Normalized Likelihood
S Ueckert, MK Riviere, F Mentre
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 42, S56-S57, 2015
22015
dfcomb: An R-package for phase I/II trials of drug combinations
MK Riviere, JH Jourdan, S Zohar
Computer methods and programs in biomedicine 125, 117-133, 2016
12016
Response to comments on ‘Competing designs for drug combination in phase I dose‐finding clinical trials’ by G. Yin, R. Lin and N. Wages
MK Riviere, F Dubois, S Zohar
Statistics in medicine 34 (1), 23-26, 2015
12015
Comments on ‘A comparative study of adaptive dose‐finding designs for phase I oncology trials of combination therapies’
MK Riviere, S Zohar
Statistics in Medicine 35 (3), 475-478, 2016
2016
Evaluation of the expected Fisher information matrix without linearization, in nonlinear mixed effect models for discrete and continuous outcomes
MK Riviere, S Ueckert, F Mentré
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 42, S27-S27, 2015
2015
Evaluation of the Expected Fisher Information Matrix without Linearization, in Nonlinear Mixed Effect Models for Discrete and Continuous Outcomes
MK Riviere, S Ueckert, F Mentre
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 42, S27-S27, 2015
2015
Designs adaptifs de recherche de dose en oncologie dans le cadre de combinaisons de molécules et de molécules ciblées
MK Rivière
Paris 7, 2014
2014
Designs Adaptifs de Recherche de Dose en Oncologie Dans Le Cadre de Combinaisons de Molécules Et de Molécules Ciblées
MK Rivière
2014
The system can't perform the operation now. Try again later.
Articles 1–15